

Thiol-Containing Metallo- β -Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem

Kamaleddin Haj Mohammad Ebrahim Tehrani, and Nathaniel I. Martin

ACS Infect. Dis., **Just Accepted Manuscript** • DOI: 10.1021/acsinfecdis.7b00094 • Publication Date (Web): 18 Aug 2017

Downloaded from <http://pubs.acs.org> on August 21, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



Thiol-Containing Metallo- β -Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem

Kamaleddin Haj Mohammad Ebrahim Tehrani^a and Nathaniel I. Martin^{a,}*

^aDepartment of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; Tel: +31 (0)6 1878 5274; Fax: +31 (0)30 - 253 6655; E-mail: n.i.martin@uu.nl

ABSTRACT

The prevalence of infections caused by metallo- β -lactamase (MBL) expressing Gram-negative bacteria has grown at an alarming rate in recent years. Despite the fact that MBLs can deactivate virtually all β -lactam antibiotics, there are as of yet no approved drugs available that inhibit their activity. We here examine the ability of previously-reported thiol-based MBL inhibitors to synergize with meropenem and cefoperazone against a panel of Gram-negative carbapenem-resistant isolates expressing different β -lactamases. Among the compounds tested, thiomandelic acid **3** and 2-mercapto-3-phenylpropionic acid **4** were found to efficiently potentiate the activity of meropenem, especially against an IMP producing strain of *K. pneumoniae*. In light of the zinc-dependent hydrolytic mechanism employed by MBLs, biophysical studies using isothermal titration calorimetry were also performed revealing a correlation between the synergistic activity of thiols **3** and **4** and their zinc-binding ability with measured K_d values of 9.8 and 20 μ M respectively.

KEYWORDS:

Antibiotic Resistance, metallo- β -lactamase, MBL inhibitor, zinc binding, synergy

INTRODUCTION

Resistance to β -lactam antibiotics poses a serious threat to human health. The enzymes responsible for such resistance are the β -lactamases and are especially prevalent among Gram-negative bacteria.^{1,2} These enzymes are divided in two classes: the serine β -lactamases (SBLs) which hydrolyze beta lactam ring by a serine nucleophile in their active site; and the metallo- β -lactamases (MBLs) whose mechanism relies upon the presence of one or two active site zinc ions.³ These zinc ions stabilize a nucleophilic hydroxide species that is believed to be the active agent in the hydrolysis the β -lactam ring leading to antibiotic inactivation. The best-studied MBLs include the NDM (New Delhi metallo-beta-lactamase), VIM (Verona integron-encoded metallo- β -lactamase) and IMP (imipenemase) enzymes which collectively exhibit a broad substrate specificity and hydrolyze antibiotics from all known beta-lactam classes.⁴

The global concern relating to antibiotic resistance has led to a number of different strategies aimed at addressing the problem. One such approach involves the co-administration of antibiotic adjuvants capable of maintaining the activity of existing antibiotics.⁵ This strategy is widely effective in treating infections due to bacteria that express SBLs. Clinically relevant SBL inhibitors include clavulanic acid, sulbactam, tazobactam and avibactam which effectively protect β -lactam antibiotics from inactivation when administered as combination therapies. By comparison, there are no clinically used MBL inhibitors available for use in addressing the growing threat posed to the β -lactam arsenal by these enzymes.

Attempts to identify inhibitors of the MBLs have revealed a number of compound classes that display promising activities when tested using *in vitro* enzyme inhibition assays.⁶ Such compounds include small molecules that contain functionalities often associated with zinc binding such as: thiols, dicarboxylates, hydroxamates, aryl sulfonamides, *N*-arylsulfonyl

1
2
3 hydrazones and tetrazole-based compounds.^{3,7,8} Among the known MBL inhibitors, sulfur-
4 containing small molecules containing either a free thiol or a sulfur atom masked as a
5 heterocycle^{9,10} are among the best characterized.^{3,7,11–15} Structures as simple as
6 mercaptoacetic acid and mercaptopropionic acid have been shown to be effective inhibitors
7 of the IMP-1 enzyme ($K_i = 0.23 \mu\text{M}$ and $0.19 \mu\text{M}$ respectively).¹⁶ Follow-up studies
8 identified higher analogs of mercapto-carboxylic acids including 2-arylmethyl-2-
9 mercaptoacetic acids and their thioesters as potent MBL inhibitors with IC_{50} values in the
10 low-nanomolar range.¹⁷ Similarly, thiomandelic acid was found to be a broad-spectrum
11 inhibitor of different MBLs including BCII ($K_i = 0.34 \mu\text{M}$), IMP-1 ($K_i = 0.029 \mu\text{M}$), IMP-2
12 ($K_i = 0.059 \mu\text{M}$) and VIM-1 ($K_i = 0.230 \mu\text{M}$)¹⁸ and 2- ω -phenylpropyl-3-mercapto
13 propionic acid has been reported as potent inhibitor of VIM-2 ($K_i = 0.220 \mu\text{M}$).^{19,20} Other examples of
14 structurally similar MBL inhibitors include compounds containing a free thiol with a
15 neighboring carbonyl functionality such as α -mercaptoacetophenone,²¹ thiosalicylic acid,¹⁸
16 and interestingly, the dipeptide drug captopril which is used in the treatment of
17 hypertension.²² The inhibitory activity of these molecules is attributed to the ability of the
18 thiol group to chelate the zinc ion present in the MBL active site as supported by several X-
19 ray crystallography studies.^{21,23–26}

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 The inhibitory activity of thiol-containing small molecules against clinically relevant
46 MBLs *in vitro* prompted us to conduct a series of antibacterial assays to evaluate the
47 synergistic activity of such compounds with the representative β -lactams meropenem and
48 cefoperazone. To do so, the sensitizing effects of thiols **1-5** (Fig. 1) on the activity of
49 meropenem and cefoperazone were assessed against a panel of Gram-negative bacteria
50 expressing various β -lactamases. The stability of the thiols was also assessed under the assay
51 condition employed and isothermal titration calorimetry (ITC) was used to measure the zinc-
52 binding affinity of the most synergistically-active compounds.
53
54
55
56
57
58
59
60




Figure 1. Thiol-based MBL inhibitors and disulfides evaluated for synergy with meropenem and cefoperazone in the current study.

RESULTS AND DISCUSSION

Thiols **1-5** were initially tested alone for antibacterial activity against a panel of carbapenem-resistant Gram-negative pathogens expressing MBLs including NDM, VIM and IMP or SBLs such as KPC-2 and OXA-48. These studies revealed that none of the thiols inhibited bacterial growth at the highest concentration tested of 64 $\mu\text{g}/\text{mL}$. With the exception of *P. aeruginosa* M-120 which was susceptible to meropenem, all of the MBL-expressing strains used in our study exhibited resistance to both meropenem and cefoperazone with MIC values ranging from 8 to $>256 \mu\text{g}/\text{mL}$. For use as a reference MBL inhibitor known

to synergize with β -lactam antibiotics, we turned to the work of Migliavacca and coworkers who reported a zinc chelating mixture of EDTA and 1,10-phenanthroline as being synergistic with imipenem in preventing growth of MBL-expressing strains of *Pseudomonas aeruginosa*.²⁷ We found that the EDTA/1,10-phenanthroline mixture was similarly effective in lowering the MIC of meropenem and cefoperazone against the MBL-expressing strains used in our study (Table 1). Also, and as expected, the EDTA/1,10-phenanthroline mixture showed no synergistic effect with meropenem against the two SBL-expressing strains also evaluated.

Table 1. MIC ($\mu\text{g/mL}$) of meropenem (Mer) and Ceferazone (Cef) tested alone or in combination with thiol MBL-inhibitors **3** and **4**

Isolates	Mer	Cef	Mer + 3 ^a	Cef + 3	Mer + 4	Cef + 4	Mer + EP ^b	Cef + EP ^b
<i>K. pneumoniae</i> RC10 (KPC-2)	>128	>256	128	>256	>128	>256	>128 ^c	>256 ^c
<i>K. pneumoniae</i> RC 45 (OXA-48)	64	>256	64	>256	64	>256	16 ^d	>256 ^d
<i>K. pneumoniae</i> RC51 (VIM-1)	64/32	>256	0.5 ($\geq 128^e, \leq 0.27^f$)	256	1 ($32^e, \leq 0.38^f$)	>256	$\leq 0.5^c$	8 ^c
<i>K. pneumoniae</i> JS265 (IMP-28)	16/8	256	0.125 ($128^e, \leq 0.07^f$)	≤ 2 ($\geq 128^e, \leq 0.07^f$)	0.125 ($64^e, \leq 0.13^f$)	≤ 2 ($\geq 128^e, \leq 0.07^f$)	$\leq 0.125^g$	$\leq 2^g$
<i>E. coli</i> RC89 (NDM-1)	128/64	>256	16 (8 ^e)	>256	16 (8 ^e)	>256	$\leq 1^c$	>256 ^c
<i>P. aeruginosa</i> RC60 (VIM)	32	128	4 (8 ^e , $\leq 0.38^f$)	16 (8 ^e , $\leq 0.5^f$)	8 (4 ^e)	16 (8 ^e , $\leq 0.5^f$)	0.5 ^c	8 ^c
<i>P. aeruginosa</i> JS80 (IMP)	64	256	8 (8 ^e)	8 ($32^e, \leq 0.38^f$)	8 (8 ^e , $\leq 0.5^f$)	16 ($16^e, \leq 0.25^f$)	4 ^h	4 ^g
<i>K. pneumoniae</i> RC21 (VIM-1)	64/32	>256	0.5 ($64^e, \leq 0.19^f$)	>256	1 ($32^e, \leq 0.38^f$)	>256	$\leq 0.5^g$	$\leq 2^g$
<i>E. aerogenes</i> RC22 (VIM-1)	32/16	>256	0.5 ($64^e, \leq 0.25^f$)	>256	1 ($16^e, \leq 0.38^f$)	>256	$\leq 0.25^g$	64 ^g
<i>K. pneumoniae</i> RC48 (VIM-1)	>128/128	>256	4 ($>32^e, \leq 0.38^f$)	>256	8 ($16^e, \leq 0.5^f$)	>256	$\leq 1^g$	$\leq 2^g$
<i>K. pneumoniae</i> JS22 (NDM-1)	32/16	>256	8 (4 ^e)	>256	2 ($16^e, \leq 0.38^f$)	>256	$\leq 0.5^g$	>256 ^g
<i>K. pneumoniae</i> JS177 (NDM-1)	16/8	>256	4 (4 ^e)	>256	1 (8 ^e)	>256	$\leq 0.25^g$	>256 ^g
<i>K. pneumoniae</i> JS37 (NDM-1)	64/32	>256	16 (4 ^e)	>256	16 (4 ^e)	>256	$\leq 1^g$	>256 ^g
<i>P. aeruginosa</i> M-120 (IMP)	<1	128/64	n.d.	2 ($32^e, \leq 0.25^f$)	n.d.	4 ($16^e, \leq 0.38^f$)	n.d.	4 (32) ^d

^a Thiols **3** and **4** added at 64 $\mu\text{g/mL}$. None of the thiols inhibited growth at this concentration when tested alone.

^b EP = EDTA/1,10-phenanthroline mixture

^c EP mixture applied at 16 $\mu\text{g/mL}$ EDTA and 1 $\mu\text{g/mL}$ 1,10-phenanthroline.

^d EP mixture applied at 64 $\mu\text{g/mL}$ EDTA and 4 $\mu\text{g/mL}$ 1,10-phenanthroline.

^e Fold reduction of MIC. Reduction of MIC greater than 8-fold shown in bold.

^f Lowest FIC measured (FIC < 0.5 regarded as an indication of synergy).

^g EP mixture applied at 32 $\mu\text{g/mL}$ EDTA and 2 $\mu\text{g/mL}$ 1,10-phenanthroline.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

With a reliable reference system in hand, the capacity for thiols **1-5** to synergize with meropenem was next investigated. Table 1 shows the synergy data of the two most potent thiols **3** and **4** (see supplemental information Table S2 for complete activity data for compounds **1-5**). Captopril **1** exhibited moderate to weak synergy at a concentration of 64 $\mu\text{g}/\text{mL}$ while thiosalicylic acid **2** displayed no appreciable synergy when tested at the same concentration. By comparison, when administered at 64 $\mu\text{g}/\text{mL}$ thiols **3** and **4** significantly lowered the MIC of meropenem against all the MBL-producing isolates tested. The activity of compound **5** was also promising but interestingly was limited to the only two *Klebsiella* strains tested. Thiols **3-5** have previously been shown to be more potent MBL inhibitors than compounds **1** and **2** in biochemical enzyme inhibition assays^{17,18,21,23} and our MIC synergy results follow the same trend. Notably, for compounds **3** and **4** we observed broad-spectrum, and in some cases, potent synergistic activity with meropenem against the MBL-producing isolates evaluated. Building on the encouraging results of the preliminary synergy assays (carried out at fixed thiol concentration of 64 $\mu\text{g}/\text{mL}$) we next performed a series of checkerboard synergy assays in which the MIC of meropenem was determined at varying concentrations of inhibitors **1-5**. Such an approach provides for a better picture of the synergistic relationship between the two combined agents and allows for determination of the fractional inhibitory concentration (FIC) index. Briefly, FIC values are calculated by adding the following two fractional values: (MIC of compound A in combination/MIC of compound A alone) + (MIC of compound B in combination/MIC of compound B alone). In general, an FIC index value <0.5 is regarded as an indication of synergy.²⁸ A complete overview of all the checkerboard assays performed as well as the corresponding FIC index values is provided in the supplemental information. Among the MBL-expressing strains used the two *Klebsiella* isolates were most effectively resensitized to the meropenem when administered in combination with thiols **3-5**. Of particular note, compounds **3** and **4** were both found to

1
2
3 significantly potentiate meropenem against the IMP-28 producing *Klebsiella* strain tested
4 with FIC values ≤ 0.07 and ≤ 0.13 respectively (based on the concentrations tested, see table 1
5
6 for checkerboard FIC data of thiols **3** and **4** and supplemental information for graphical
7
8 representation of checkerboard assays).
9
10
11

12
13 Thiols are well known for their tendency to form homo- or heterodisulfides in
14 biological systems. Such reactivity is of special importance in the case of thiol-based MBL
15 inhibitors such as compounds **1-5** as it has been reported that in their disulfide form their
16 activity is significantly reduced.¹⁸ In this regard we selected compounds **3-5** as the three most
17 active thiols from our synergy assays and monitored their conversion to the corresponding
18 disulfides under the assay conditions used. Thiols **3-5** were thus incubated in Mueller-Hinton
19 broth at 37 °C and sample aliquots analyzed at time points ranging from 0 to 8 hours. As
20 shown in figure 2, thiols **3** and **4** were found to form their corresponding disulfides (**6** and **7**
21 respectively) with half-lives of ca. 5 hours. By comparison, thiol **5** was oxidized to **8** more
22 rapidly with a half-life in the range of minutes which may also explain its lower level of
23 synergy relative to **3** and **4**. Disulfides **6-8** were synthesized for use as reference compounds
24 in the stability assays and were evaluated for their synergy with meropenem against the two
25 most susceptible *Klebsiella* isolates identified (Supplemental Table S20). The three disulfides
26 exhibited very low levels of synergy relative that of the corresponding free thiols. The slight
27 synergy observed for these disulfides may in fact be attributable to a reductive process carried
28 out by the bacteria themselves to release a small amount of the more active thiol. Many
29 bacteria contains redox active enzymes capable of disulfide reduction both in cytoplasm and
30 periplasmic space.²⁹
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2. Time-dependent oxidation of thiols 3-5 to corresponding disulfides 6-8 by incubation in Mueller-Hinton broth at 37 °C.

The superior synergistic activity and relative stability of thiols 3 and 4 prompted us to further characterize their zinc binding abilities using isothermal titration calorimetry (ITC). To do so a solution of zinc chloride was titrated into the sample well containing either 3 or 4 (both 3 and 4 were both to be found stable in the buffer conditions used for the ITC experiments) and the heat of binding monitored. In this way a number of thermodynamic

1
2
3 binding parameters are revealed including K_d (dissociation constant), ΔH (enthalpy), ΔG
4 (Gibbs free energy) and ΔS (entropy). As shown in figure 3, compounds **3** and **4** exhibited
5 high affinities for Zn^{2+} with K_d values of 9.8 and 20.0 μM respectively. Also of note was the
6 lack of any measurable binding interaction when zinc chloride was titrated into solutions of
7 disulfides **6** and **7**. The zinc binding abilities of the reference compounds EDTA and 1,10-
8 phenanthroline were also assessed using ITC showing a strong interaction (Supplemental
9 figures S3 and S4). The results of these ITC studies correlate well with the synergy data
10 obtained and suggest that zinc binding may be a useful predictor for a compound's ability to
11 resensitize MBL-expressing organisms to beta-lactam antibiotics. Furthermore, the relative
12 ease with which ITC can be used to assess zinc binding by small molecules may make it a
13 complimentary technique for identifying new lead compounds capable of effectively
14 inhibiting MBLs.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32



53
54
55
56
57
58
59
60
Figure 3. ITC Thermograms for binding of Zn^{2+} by thiols **3** (A) and **4** (B). A solution of zinc chloride (2.0 mM) was titrated into the sample cell containing thiol **3** or **4** (0.2 mM). Thermodynamic parameters shown based on triplicate binding assays and the reported as mean \pm SE. Errors estimated via Monte Carlo simulations using the error of individual experiments.

CONCLUSION

While small molecule thio-carbonyl compounds have previously been shown to inhibit various MBLs, their ability to synergize with β -lactam antibiotics in overcoming MBL-associated resistance has not been extensively studied. We here demonstrate a significant level of synergism between meropenem and a series of thiols, most notably thiomandelic acid **3** and 2-merpto-3-phenylpropionic acid **4**. Combinations of meropenem with **3** or **4** exhibit antibacterial activity against a number of Gram-negative bacteria expressing different MBLs including IMP, NDM and VIM. Given the high degree of active site heterogeneity among the different types of MBL enzymes,¹¹ designing an inhibitor with potent inhibitory activity towards several types of MBL is challenging. In this light, thiomandelic acid **3** is unique given its ability to inhibit a range of MBLs and, as shown in the present study, its capacity to resensitize MBL-expressing Gram-negative isolates to meropenem, an important β -lactam antibiotic of last resort. In addition, ITC studies showed thiols **3** and **4** to be effective zinc chelators with low-micromolar K_d values supporting the proposed mechanism of action for these compounds. In this regard ITC may provide a useful means of (pre)screening for zinc-binding MBL inhibitors. While compounds **3** and **4** exhibit potent synergy with meropenem, their propensity to oxidize and likely ability to interact with free zinc and other metallo proteins precludes their use as clinical MBL inhibitors. In this regard, MBL inhibitors employing free thiols as zinc chelating groups are more likely to be of value as tool compounds for biochemical studies involving MBLs. Optimized analogues or other classes of MBL inhibitors capable of overcoming such pharmacokinetic hurdles present a key objective in the continued fight against antibiotic resistance.

MATERIALS AND METHODS

Materials. Potassium thioacetate was purchased from Combi-Blocks Inc. (San Diego, CA USA). Thiosalicylic acid was purchased from Fisher Scientific (Waltham, MA USA). Other reagents including captopril, 2-bromoacetophenone, *S*-mandelic acid, *L*-phenylalanine, were purchased from Sigma-Aldrich company.

Synthesis. Among the thiols selected for investigation, captopril **1** and thiosalicylic acid **2** were commercially available while compounds **3-5** required preparation via previously reported synthetic routes.^{21,30-32} Briefly, compound **3** was synthesized via esterification of *S*-mandelic acid which was followed by mesylation of the hydroxyl group. Substitution of the tosylate ester with thioacetate anion followed by acidic hydrolysis furnished **3**.³⁰ For the synthesis of compound **4**, *L*-phenylalanine was converted to its corresponding α -bromocarboxylic acid through a sodium nitrite mediated halo-deamination reaction, which was subsequently reacted with potassium thioacetate to afford *S*-acetyl derivative of **4**. Basic hydrolysis of the latter intermediate led to the final product **4**.^{31,32} Thioacetophenone **5** was prepared via a two-step procedure involving thiolation of α -bromoacetophenone with potassium thioacetate followed by a basic hydrolysis.²¹ In addition, disulfides **6-8**³³⁻³⁵ were readily prepared by reacting the corresponding thiol with iodine in water/acetonitrile.³⁶

MIC determinations and synergy assays. The antibacterial activity of compounds **1-5** was evaluated alone and in combination with meropenem against a panel of beta-lactamase producing Gram-negative bacteria including *K. pneumoniae* RC10 (KPC-2), *K. pneumoniae* RC 45 (OXA-48), *K. pneumoniae* RC51 (VIM-1), *K. pneumoniae* JS265 (IMP-28), *E. coli* RC89 (NDM-1), *P. aeruginosa* RC60 (VIM), *P. aeruginosa* JS80 (IMP), *K. pneumoniae* RC21 (VIM-1), *E. aerogenes* RC22 (VIM-1), *K. pneumoniae* RC48 (VIM-1), *K. pneumoniae* JS22 (NDM-1), *K. pneumoniae* JS177 (NDM-1), *K. pneumoniae* JS37 (NDM-1) and *P.*

1
2
3
4 *aeruginosa* M-120 (IMP). The CLSI guidelines were used to determine minimum inhibitory
5 concentrations (MICs). Starting from glycerol stocks, bacterial strains were cultured on blood
6 agar plates and incubated at 37 °C. A single colony was then transferred to tryptic soy broth
7 (TSB) and incubated with shaking at 37 °C until the optical density of the bacterial
8 suspension reached a level equivalent to the 0.5 McFarland standard. The suspension was
9 then diluted to 10⁶ CFU/mL in Mueller-Hinton broth (MHB). Using polypropylene microtiter
10 plates, the wells of the first row received 50 μL of the test compounds dissolved in MHB and
11 were subjected to serial dilution. Finally, 50 μL of the bacterial suspension was added and the
12 plates were sealed and incubated at 37 °C with constant shaking (at 600 RPM). The next
13 morning, the plates were inspected for visible bacterial growth.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 Synergy between meropenem (or cefoperazone) and thiols **1-5** was evaluated as follows: To
29 the top row of a 96 well plate, 100 μL of a solution of meropenem at 4x MIC was added. 50
30 μL aliquots of this solution was serially diluted down each row to achieve a range of
31 decreasing meropenem concentrations. Next, thiols **1-5** (50 μL aliquots) were added to the
32 wells to provide a concentration range of 128 to 16 μg/mL. The relevant bacterial suspension
33 (100 μL/well) was finally added to each well to give a final concentration of thiols **1-**
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5 ranging from 64 to 8 μg/mL. The plates were sealed and incubated overnight at 37 °C.
MICs were determined the next morning by visual inspection and used in calculating
fractional inhibitory concentration index (FICI) values. As a standard MBL inhibitor cocktail,
a 16:1 (w/w) mixture of ethylenediaminetetraacetic acid disodium salt-phenanthroline (EP)
was also used. The MIC of the EP mixture was first determined against each strain so that a
sub-MIC concentrations could be used for synergy assays. All the assays were performed in
duplicates. Supplemental tables S3-S17 provide a graphical representation of the
checkerboard assays.

1
2
3 **Stability analysis.** To prepare calibration curves for thiols **3-5** and the corresponding
4 disulfides **6-8** each compound was dissolved in DMSO to prepare a stock solution (10
5 mg/mL) that was then immediately diluted in Mueller-Hinton broth (MHB) to reach
6 concentrations ranging from 1 $\mu\text{g/mL}$ to 256 $\mu\text{g/mL}$. The samples were then processed as
7 follows: To precipitate undesired media components, the sample solutions were diluted with
8 acetonitrile (1:3 v/v), vortexed for 10 seconds, and centrifuged at 10000 rpm for 10 min. The
9 supernatant was retained and stored at -20 °C until HPLC analysis. Samples were analyzed
10 by analytical RP-HPLC using a Phenomenex Gemini C-18 110A column (250×4.60 mm, 5
11 micron) at a flow rate of 1 mL/min and their UV absorbance were detected at 214 nm. For the
12 analysis of compounds **4**, **5**, **7**, and **8**, the gradient started with 0% of buffer B (95%
13 acetonitrile, 0.1% TFA) and 100% buffer A (5% acetonitrile, 0.1% TFA) increasing to 50%
14 buffer B over 5 min followed by an increase to 100% buffer B over 10 min and maintenance
15 at 100% buffer B for 3 min. The buffer gradient was then returned to 0% buffer B in 2 min
16 and maintained at 0% for an additional 5 min to re-equilibrate the system. For the analysis of
17 compounds **3** and **6** the gradient started with 0% of buffer B, increased to 50% buffer B over
18 5 min, then to 90% buffer B over 8 min followed by a final increase to 100% buffer B over 1
19 min. After 1 min at 100% buffer B the gradient returned to 0% buffer B over 2 min and was
20 maintained at 0% for 3 min to re-equilibrate the system. The calibration curves were linear
21 from 2-256 $\mu\text{g/mL}$ for compounds **3-6** and from 1.6-200 $\mu\text{g/mL}$ for compounds **7** and **8** with
22 $r^2 > 0.990$ in all the cases. Due to the relatively short half-life of compound **5** in MHB, the
23 medium needed to be supplemented with 5.0 mM TCEP to obtain a suitable calibration curve.
24
25 To assess the half-lives of thiols **3-5** in MHB, each compound was dissolved in MHB (200
26 $\mu\text{g/mL}$) and incubated at 37 °C. At time points of 0, 0.5, 1, 2, 4 and 8 hours, 100 μL aliquots
27 of each samples were taken and subjected to the same processing described above for the
28 standards prior to HPLC analysis.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. The concentrations of the metal/ligands used for the ITC experiments

Experiment (metal:ligand)	Zinc chloride concentration (mM)	Ligand concentration (mM)
ZnCl ₂ : compound 3/4/6/7	2.0	0.2
ZnCl ₂ : EDTA	0.4	0.04
ZnCl ₂ : 1,10-phenanthroline	1.0	0.1

Isothermal titration calorimetry. ITC experiments were performed using a MicroCal Auto-ITC200 instrument (Malvern). The test compounds and zinc chloride were dissolved in Tris.HCl buffer (20 mM, pH 7.0) and degassed using a sonication bath (10 min) before running the experiments. The zinc chloride solution was titrated into a solution of **3**, **4**, **6**, **7**, EDTA, or 1,10-phenanthroline (see Table 3 for specific concentrations used) over 26 aliquots of 1.5 μL (except the first injection which was 0.5 μL) with 120 seconds spacing between injections. All the experiments were performed at 25 °C in triplicate with reference power set at 2.0 $\mu\text{cal}/\text{sec}$. The generated peaks were integrated using Origin 7.0 software. The error for all the reported thermodynamic parameters was estimated through Monte Carlo simulation the standard errors of three experiments.

ASSOCIATED CONTENT

Supporting Information

Spectral characterization of compounds **3-8** including ¹H-NMR, ¹³C-NMR and high-resolution mass spectrometry data. Tables of antibiotic susceptibility and checkerboard synergy assays using meropenem or cefoperazone combined with thiols **1-5** or disulfides **6-8** (tables S1-S20). ITC thermograms of binding interactions between Zn²⁺ and thiols **3** and **4**,

1
2
3 disulfides **6** and **7**, 1,10-phenanthroline and EDTA (figures S1-S9). This material is available
4
5 free of charge via the Internet at <http://pubs.acs.org>.
6
7
8

9 10 **AUTHOR INFORMATION**

11 12 13 **Corresponding Author**

14
15 n.i.martin@uu.nl
16
17

18 19 **Funding Sources**

20
21 No competing financial interests have been declared. Financial support provided by Utrecht
22
23 University and the Netherlands Organization for Scientific Research (VIDI grant to NIM).
24
25
26
27

28 29 **ACKNOWLEDGMENT**

30
31 The authors thank Dr. Ad Fluit (Utrecht University Medical Center) and Dr. Sandra
32
33 Bernhards (Leiden University Medical Center) for kindly supplying the carbapenem-resistant
34
35 clinical isolates. We also thank Laurens Kleijn for useful discussions and assistance with ITC
36
37 measurements and Javier Sastre-Torano for assistance in developing the LC-MS assays and
38
39 performing high-resolution mass measurements.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
REFERENCES

- (1) Worthington, R. J., and Melander, C. (2013) Overcoming Resistance to β -Lactam Antibiotics. *J. Org. Chem.* *78*, 4207–4213.
- (2) Bush, K. (2015) Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check. *ACS Infect. Dis.* *1*, 509–511.
- (3) Buynak, J. D. (2013) β -Lactamase inhibitors: a review of the patent literature (2010 - 2013). *Expert Opin. Ther. Pat.* *23*, 1469–1481.
- (4) Palzkill, T. (2013) Metallo- β -lactamase structure and function. *Ann. N. Y. Acad. Sci.* *1277*, 91–104.
- (5) Wright, G. D. (2016) Antibiotic Adjuvants: Rescuing Antibiotics from Resistance. *Trends Microbiol.* *24*, 862–871.
- (6) McGeary, R. P., Tan, D. T. C., and Gerhard, S. (2017) Progress toward inhibitors of metallo- β -lactamases. *Future Med. Chem.* *9*, 673–691.
- (7) Faridoon, and Ul Islam, N. (2013) An update on the status of potent inhibitors of Metallo- β -lactamases. *Sci. Pharm.* *81*, 309–327.
- (8) Li, G.-B., Abboud, M. I., Brem, J., Someya, H., Lohans, C. T., Yang, S.-Y., Spencer, J., Wareham, D. W., McDonough, M. A., and Schofield, C. J. (2017) NMR-filtered virtual screening leads to non-metal chelating metallo- β -lactamase inhibitors. *Chem. Sci.* *8*, 928–937.
- (9) Falconer, S. B., Reid-Yu, S. A., King, A. M., Gehrke, S. S., Wang, W., Britten, J. F., Coombes, B. K., Wright, G. D., and Brown, E. D. (2015) Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing

1
2
3 Klebsiella pneumoniae. *ACS Infect. Dis.* 1, 533–543.

4
5
6 (10) Chan, A. N., Shiver, A. L., Wever, W. J., Razvi, S. Z. A., Traxler, M. F., and Li, B.
7
8 (2017) Role for dithiolopyrrolones in disrupting bacterial metal homeostasis. *Proc. Natl.*
9
10 *Acad. Sci.* 114, 2717–2722.

11
12
13 (11) Fast, W., and Sutton, L. D. (2013) Metallo- β -lactamase: Inhibitors and reporter
14
15 substrates. *Biochim. Biophys. Acta - Proteins Proteomics* 1834, 1648–1659.

16
17
18 (12) Chang, Y.-N., Xiang, Y., Zhang, Y.-J., Wang, W.-M., Chen, C., Oelschlaeger, P., and
19
20 Yang, K.-W. (2017) Carbamylmethyl Mercaptoacetate Thioether: A Novel Scaffold for the
21
22 Development of L1 Metallo- β -lactamase Inhibitors. *ACS Med. Chem. Lett.* 8, 527–532.

23
24
25 (13) Shin, W. S., Bergstrom, A., Bonomo, R. A., Crowder, M. W., Muthyala, R., and Sham,
26
27 Y. Y. (2017) Discovery of 1-Hydroxypyridine-2(1H)-thione-6-carboxylic Acid as a First-in-
28
29 Class Low-Cytotoxic Nanomolar Metallo β -Lactamase Inhibitor. *ChemMedChem* 12, 845–
30
31 849.

32
33
34 (14) Skagseth, S., Akhter, S., Paulsen, M. H., Muhammad, Z., Lauksund, S., Samuelsen, Ø.,
35
36 Leiros, H.-K. S., and Bayer, A. (2017) Metallo- β -lactamase inhibitors by bioisosteric
37
38 replacement: Preparation, activity and binding. *Eur. J. Med. Chem.* 135, 159–173.

39
40
41 (15) Seville, L., Gavara, L., Bebrone, C., De Luca, F., Nauton, L., Achard, M., Mercuri, P.,
42
43 Tanfoni, S., Borgianni, L., Guyon, C., Lonjon, P., Turan-Zitouni, G., Dzieciolowski, J.,
44
45 Becker, K., Bénard, L., Condon, C., Maillard, L., Martinez, J., Frère, J.-M., Dideberg, O.,
46
47 Galleni, M., Docquier, J.-D., and Hernandez, J.-F. (2017) 1,2,4-Triazole-3-thione
48
49 Compounds as Inhibitors of Zinc Metallo- β -lactamases. *ChemMedChem* 12, 972–985.

50
51
52 (16) Arakawa, Y., Shibata, N., Shibayama, K., Kurokawa, H., Yagi, T., Fujiwara, H., and
53
54 Goto, M. (2000) Convenient test for screening metallo-beta-lactamase-producing gram-
55
56
57
58
59
60

1
2
3 negative bacteria by using thiol compounds. *J. Clin. Microbiol.* 38, 40–43.
4

5
6 (17) Hammond, G. G., Huber, J. L., Greenlee, M. L., Laub, J. B., Young, K., Silver, L. L.,
7
8 Balkovec, J. M., Pryor, K. A. D., Wu, J. K., Leiting, B., Pompliano, D. L., and Toney, J. H.
9
10 (1999) Inhibition of IMP-1 metallo- β -lactamase and sensitization of IMP-1-producing
11
12 bacteria by thioester derivatives. *FEMS Microbiol. Lett.* 179, 289–296.
13
14

15
16 (18) Mollard, C., Moali, C., Papamicael, C., Damblon, C., Vessilier, S., Amicosante, G.,
17
18 Schofield, C. J., Galleni, M., Frère, J. M., and Roberts, G. C. K. (2001) Thiomandelic acid, a
19
20 broad spectrum inhibitor of zinc β -lactamases. Kinetic and spectroscopic studies. *J. Biol.*
21
22 *Chem.* 276, 45015–45023.
23
24

25
26 (19) Jin, W., Arakawa, Y., Yasuzawa, H., Taki, T., Hashiguchi, R., Mitsutani, K., Shoga, A.,
27
28 Yamaguchi, Y., Kurosaki, H., Shibata, N., Ohta, M., and Goto, M. (2004) Comparative Study
29
30 of the Inhibition of Metallo- β -Lactamases (IMP-1 and VIM-2) by Thiol Compounds That
31
32 Contain a Hydrophobic Group. *Biol. Pharm. Bull.* 27, 851–856.
33
34

35
36 (20) Yamaguchi, Y., Jin, W., Matsunaga, K., Ikemizu, S., Yamagata, Y., Wachino, J. I.,
37
38 Shibata, N., Arakawa, Y., and Kurosaki, H. (2007) Crystallographic investigation of the
39
40 inhibition mode of a VIM-2 metallo- β -lactamase from *Pseudomonas aeruginosa* by a
41
42 mercaptocarboxylate inhibitor. *J. Med. Chem.* 50, 6647–6653.
43
44
45

46
47 (21) Liénard, B. M. R., Garau, G., Horsfall, L., Karsisiotis, A. I., Damblon, C., Lassaux, P.,
48
49 Papamicael, C., Roberts, G. C. K., Galleni, M., Dideberg, O., Frère, J.-M., and Schofield, C.
50
51 J. (2008) Structural basis for the broad-spectrum inhibition of metallo- β -lactamases by thiols.
52
53 *Org. Biomol. Chem.* 6, 2282–2294.
54
55

56
57 (22) Klingler, F. M., Wichelhaus, T. A., Frank, D., Cuesta-Bernal, J., El-Delik, J., Müller, H.
58
59 F., Sjuts, H., Göttig, S., Koenigs, A., Pos, K. M., Pogoryelov, D., and Proschak, E. (2015)
60

1
2
3 Approved drugs containing thiols as inhibitors of metallo- β -lactamases: Strategy to combat
4 multidrug-resistant bacteria. *J. Med. Chem.* *58*, 3626–3630.

5
6
7
8
9 (23) Brem, J., Van Berkel, S. S., Zollman, D., Lee, S. Y., Gileadi, O., McHugh, P. J., Walsh,
10 T. R., McDonough, M. A., and Schofield, C. J. (2016) Structural basis of metallo- β -lactamase
11 inhibition by captopril stereoisomers. *Antimicrob. Agents Chemother.* *60*, 142–150.

12
13
14
15
16
17 (24) Hinchliffe, P., González, M. M., Mojica, M. F., González, J. M., Castillo, V., and Saiz,
18 C. (2016) Cross-class metallo- β -lactamase inhibition by bisthiazolidines reveals multiple
19 binding modes. *Proc. Natl. Acad. Sci. U. S. A.* E3745–E3754.

20
21
22
23
24
25 (25) Karsisiotis, A. I., Damblon, C. F., and Roberts, G. C. K. (2013) Solution structures of
26 the *Bacillus cereus* metallo- β -lactamase BcII and its complex with the broad spectrum
27 inhibitor R-thiomandelic acid. *Biochem. J.* *456*, 397–407.

28
29
30
31
32
33 (26) Brem, J., van Berkel, S. S., Aik, W., Rydzik, A. M., Avison, M. B., Pettinati, I., Umland,
34 K.-D., Kawamura, A., Spencer, J., Claridge, T. D. W., McDonough, M. A., and Schofield, C.
35 J. (2014) Rhodanine hydrolysis leads to potent thioenolate mediated metallo- β -lactamase
36 inhibition. *Nat. Chem.* *6*, 1084–1090.

37
38
39
40
41
42
43 (27) Migliavacca, R., Docquier, J.-D., Mugnaioli, C., Amicosante, G., Daturi, R., Lee, K.,
44 Rossolini, G. M., and Pagani, L. (2002) Simple microdilution test for detection of metallo- β -
45 lactamase production in *Pseudomonas aeruginosa*. *J. Clin. Microbiol.* *40*, 4388–90.

46
47
48
49
50
51 (28) Odds, F. C. (2003) Synergy, antagonism, and what the checkerboard puts between them.
52
53
54
55
56
57
58
59
60
J. Antimicrob. Chemother. *52*, 1.

(29) Ritz, D., and Beckwith, J. (2001) Roles of thiol-redox pathways in bacteria. *Annu. Rev.*
Microbiol. *55*, 21–48.

1
2
3
4 (30) Strijtveen, B., and Kellogg, R. M. (1986) Synthesis of (racemization prone) optically
5 active thiols by SN2 substitution using cesium thiocarboxylates. *J. Org. Chem.* 51, 3664–
6 3671.
7
8

9
10
11 (31) Coric, P., Turcaud, S., Meudal, H., Roques, B. P., and Fournie-Zaluski, M.-C. (1996)
12 Optimal Recognition of Neutral Endopeptidase and Angiotensin-Converting Enzyme Active
13 Sites by Mercaptoacyldipeptides as a Means To Design Potent Dual Inhibitors. *J. Med.*
14 *Chem.* 39, 1210–1219.
15
16

17
18
19 (32) Chen, J. G., Zhu, J., Skonezny, P. M., Rosso, V., and Venit, J. J. (2004) Crystallization-
20 Induced Chiral Inversion As the Key Step for Synthesis of (S)-2-Acetylthio-3-
21 phenylpropanoic Acid from l-Phenylalanine. *Org. Lett.* 6, 3233–3235.
22
23
24

25
26
27 (33) Bonner, W. A. (1968) Preparation, resolution, and absolute configuration of .alpha.-
28 mercaptophenylacetic acid. *J. Org. Chem.* 33, 1831–1836.
29
30
31

32
33
34 (34) Chandanshive, J. Z., Bonini, B. F., Gentili, D., Fochi, M., Bernardi, L., and Franchini,
35 M. C. (2010) Regiocontrolled synthesis of ring-fused thieno[2,3-c]pyrazoles through 1,3-
36 dipolar cycloaddition of nitrile imines with sulfur-based acetylenes. *European J. Org. Chem.*
37 6440–6447.
38
39
40

41
42
43 (35) Biilmann, E., and Madsen, E. H. (1914) Studien über organische Thiosäuren V. Über die
44 Einwirkung von Kaliumxanthogenat auf Brommalonsäuren. *Justus Liebig's Ann. der Chemie*
45 402, 331–342.
46
47
48

49
50
51 (36) Zeynizadeh, B. (2002) Oxidative Coupling of thiols to disulfides with iodine in wet
52 acetonitrile. *J. Chem. Res.* 564–566.
53
54
55
56
57
58
59
60

FOR TABLE OF CONTENTS USE ONLY

Thiol-Containing Metallo- β -Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem*Kamaleddin Haj Mohammad Ebrahim Tehrani^a and Nathaniel I. Martin^{a,*}*